Polycyclo Ring System Patents (Class 564/308)
  • Patent number: 10069070
    Abstract: A method of purifying an organic material using an ionic liquid according to the present invention includes a sublimation step (S510) of sublimating the organic material containing an impurity, a capturing step (S520) of bringing a sublimated gas of the organic material into contact with the flowing ionic liquid to capture the sublimated gas, and a recrystallization step (S530) of preferentially oversaturating the organic material, which is to be purified, of the sublimated gas, which is captured in the ionic liquid to be dissolved, to thus generate the recrystallized organic material. In the present invention, it is not necessary to perform a process of carrying the sublimated gas, which is generated during the sublimation step, to implement reverse sublimation. Accordingly, there is a merit in that the contamination of a purified sample by an inert carrier gas, which is used in a conventional sublimation purification method, is fundamentally avoided.
    Type: Grant
    Filed: February 11, 2015
    Date of Patent: September 4, 2018
    Assignee: ILSOLED CO., LTD.
    Inventor: Tae Won Kim
  • Patent number: 9522888
    Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: August 20, 2015
    Date of Patent: December 20, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
  • Patent number: 9072699
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: July 7, 2015
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
  • Patent number: 9055743
    Abstract: The present application relates to novel alpha, beta-unsaturated imines, to processes for their preparation, to their use for controlling animal pests including arthropods and in particular insects and to their use in the control of vectors.
    Type: Grant
    Filed: November 24, 2011
    Date of Patent: June 16, 2015
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Stefan Werner, Ulrich Ebbinghaus-Kintscher, Sebastian Horstmann, Michael Maue, Hans-Georg Schwarz, Robert Velten, Arnd Voerste, Ulrich Görgens, Andreas Turberg
  • Publication number: 20150119582
    Abstract: Naphthyl-containing compounds having structural formula S2R for use in organic light-emitting diodes (OLEDs). R may include an aromatic group, a heterocyclic group, or a group that is both aromatic and heterocylic. In some examples, R is phenyl, biphenyl, and thiophenyl. OLEDs including these compounds are shown to emit in a range between 400 nm and 700 nm. These OLEDs are suitable for devices including televisions, laptop computers, computer monitors, personal digital assistants, mobile phones, portable media players, watches, test devices, advertising displays, information displays, indication displays, and large-area light-emitting elements for general illumination.
    Type: Application
    Filed: May 8, 2013
    Publication date: April 30, 2015
    Inventor: Carl WAGNER
  • Publication number: 20150119396
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: October 22, 2012
    Publication date: April 30, 2015
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Angeles Estiarte Martínez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Publication number: 20150102321
    Abstract: Compounds according to Formula 1, devices containing the same and formulations containing the same are described. Formula 1 has the following structure: where at least two of R1-R10 are not H, where at least one of R1-R10 has the formula T1 where L is an organic linker, where Y1 to Y4 are CR or N, where adjacent R moieties can form fused rings, where Rs and Rt are independently aryl or heteroaryl, either of which may independently be further substituted, and where Rs and Rt do not form fused rings with any part of the molecule.
    Type: Application
    Filed: September 15, 2014
    Publication date: April 16, 2015
    Inventors: Raymond Kwong, Kit Yee Tsang, Sze Kui Lam
  • Publication number: 20150084031
    Abstract: A polymerizable monomer represented by the following formula (1) wherein at least one of Ar1 to Ar3 is substituted by a group represented by the following formula (2) and which is substituted by one or more groups comprising a polymerizable functional group. Ar1 to Ar3 are a substituted or unsubstituted aryl group having 6 to 40 ring carbon atoms, Ar6 is a substituted or unsubstituted aryl group having 6 to 40 ring carbon atoms and Ar4 and Ar5 are a substituted or unsubstituted arylene group having 6 to 40 ring carbon atoms.
    Type: Application
    Filed: December 2, 2014
    Publication date: March 26, 2015
    Inventors: Mitsuru EIDA, Nobohiro YABUNOUCHI, Yumiko MIZUKI, Masami WATANABE, Akinori YOMOGITA
  • Publication number: 20150065730
    Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Application
    Filed: January 21, 2013
    Publication date: March 5, 2015
    Inventors: Elvira Montenegro, Amir H. Parham, Philipp Stoessel, Teresa Mujica-Fernaud, Frank Voges, Arne Buesing
  • Patent number: 8957114
    Abstract: Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.
    Type: Grant
    Filed: December 3, 2010
    Date of Patent: February 17, 2015
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Sharon M. Laughlin, Michael J. Sizensky, Surendra P. Singh, Harold Scott Wilkinson, Cai Gu Huang, Philip James Bonasia, Susan S. D'Souza
  • Patent number: 8952249
    Abstract: 1,4 fullerene deriatives useful for solar cells are provided, where their structures allow for straightforward functionalizations to tune their properties in terms of solubility and LUMO energy levels.
    Type: Grant
    Filed: June 16, 2011
    Date of Patent: February 10, 2015
    Assignee: The Regents of the University of California
    Inventors: Alessandro Varotto, Fred Wudl, Jang Jo
  • Publication number: 20150031722
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Application
    Filed: October 6, 2014
    Publication date: January 29, 2015
    Inventors: Sara Hadida-Ruah, Anna Hazlewood, Peter Grootenhuis, Fredrick Van Goor, Ashvani Singh, Jinglan Zhou, Jason McCartney
  • Publication number: 20150018566
    Abstract: The invention provides combretastatin A-4 like compounds that are modified to have enhanced tubulin binding activity and in some embodiments the ability to promote accumulation in the vasculature undergoing angiogenesis (homing activity). The compounds are based on the combretastatin A-4 skeletal structure having a tubulin-binding pharmacophore comprising two fused rings (A and B rings) in which the B ring is substituted with (a) an aromatic ring structure (C ring) and (b) a second substituent/functional group that comes off the B ring. The aromatic ring structure is typically a six membered ring phenolic or aniline structure, or may also be a fused ring structure such as a substituted or unsubstituted naphthalene.
    Type: Application
    Filed: August 27, 2012
    Publication date: January 15, 2015
    Inventors: John Jarlath Walsh, Richard Shah, Emmet Martin McCormack, Gillian Joy Hudson, Martina White, Gary Daniel Stack, Brian William Moran, Adrian Coogan, Elaine Carmel Breen
  • Publication number: 20140377791
    Abstract: The present invention relates to a compound which is a novel two-photon absorbing fluorescent substance, a production method for the compound, a fluorescence sensor and molecular probe able to sense various substrates or enzyme activity or the like using the same, and a method of sensing enzyme activity or the like using the same. More specifically, the present invention relates to a novel two-photon absorbing fluorescent substance which has the high photo-stability and large two-photon absorption cross-section value of acedan which is a two-photon absorbing fluorescent substance, and has the high fluorescence efficiency of coumarin which is a one-photon absorbing fluorescent substance, while exhibiting absorption and emission characteristics at a longer wavelength than existing acedan and coumarin and so being advantageous in in-vivo imaging.
    Type: Application
    Filed: March 21, 2013
    Publication date: December 25, 2014
    Inventors: Kyo Han Ahn, Dokyoung Kim
  • Patent number: 8901298
    Abstract: The present invention relates to condensed aromatic compounds with multiple ring bridging of the general formulae (1), (2), (3), (4) and (5). The invention furthermore relates to the use of the compounds according to the invention in an organic electronic device and to a process for the preparation of the compounds according to the invention. The invention furthermore relates to an electronic device which comprises the compounds according to the invention.
    Type: Grant
    Filed: October 1, 2009
    Date of Patent: December 2, 2014
    Assignee: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Christof Pflumm, Holger Heil, Arne Buesing
  • Patent number: 8846950
    Abstract: An embodiment of the invention is a novel Cr(V)OCO3? trianionic pincer ligand complex. Another embodiment of the invention is a catalytic method for oxidation of a substrate aerobically in the presence of a source of oxygen, where the novel Cr(V)OCO3? trianionic pincer ligand complex acts as the catalyst. The substrate can be a phosphine, amine, sulfide, alkene, alkane or a second metal complex. Another embodiment of the invention is directed to NCN pincer ligands that can form trianionic pincer ligand complexes.
    Type: Grant
    Filed: March 3, 2010
    Date of Patent: September 30, 2014
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Adam Steven Veige, Joseph Michael Falkowski, Matthew O'Reilly, Subramaniam Kuppuswamy, Kevin P. McGowan, Soumya Sarkar
  • Publication number: 20140256729
    Abstract: The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and theft use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
    Type: Application
    Filed: October 22, 2012
    Publication date: September 11, 2014
    Inventors: Alberto Ortega Muñoz, Matthew Colin Thor Fyfe, Marc Martinell Pedemonte, Maria de los Ángeles Estiarte Martínez, Nuria Valls Vidal, Guido Kurz, Julio Cesar Castro Palomino Laria
  • Publication number: 20140235591
    Abstract: Disclosed are compounds of Formula (I) and/or a salt thereof; wherein R is —OH or —OP(O)(OH)2. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: February 20, 2014
    Publication date: August 21, 2014
    Inventors: T. G. Murali Dhar, Hai-Yun Xiao, Alaric J. Dyckman, Eric J. Chan, Marta Dabros, Daniel Richard Roberts
  • Patent number: 8802675
    Abstract: Multifunctional compounds are provided, comprising two or more functional moieties selected from: (i) a moiety that imparts an iron chelator function; (ii) a moiety that imparts a neuroprotective function; (iii) a moiety that imparts combined antiapoptotic, neuroprotective and/or neurorestorative functions; (iv) a moiety that imparts brain MAO inhibition, preferably with little or no MAO inhibition in liver and small intestine; (v) a moiety that imparts cholinesterase inhibitory function; and (vi) a moiety that imparts an N-methyl-D-aspartic acid receptor (NMDAR) inhibition, and pharmaceutically acceptable salts and optical isomers thereof. The multifunctional compounds are useful in the treatment or prevention of diseases, disorders or conditions that can be prevented and/or treated by iron chelation therapy, and/or neuroprotection and/or neurorestoration, and/or apoptosis inhibition and/or MAO inhibition and/or cholinesterase inhibition and/or NMADR inhibition.
    Type: Grant
    Filed: January 31, 2010
    Date of Patent: August 12, 2014
    Assignees: Technion Research and Development Foundation Ltd, Yeda Research and Development Company Ltd.
    Inventors: Moussa B. H. Youdim, Mati Fridkin, Hailin Zheng
  • Publication number: 20140213657
    Abstract: The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A?), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A?) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH2C(=0)NH2, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from a single bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, and —CH2CH2CH2CH2—; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy.
    Type: Application
    Filed: March 27, 2014
    Publication date: July 31, 2014
    Applicant: ORYZON GENOMICS S.A.
    Inventors: Alberto Ortega MUÑOZ, Julio CASTRO-PALOMINO LARIA, Matthew Colin Thor FYFE
  • Publication number: 20140203216
    Abstract: The present invention relates to a compound of the formula (I), (II) or (III), to the use of the compound in an electronic device, and to an electronic device comprising a compound of the formula (I), (II) or (III). The present invention furthermore relates to a process for the preparation of a compound of the formula (I), (II) or (III) and to a formulation comprising one or more compounds of the formula (I), (II) or (III).
    Type: Application
    Filed: July 5, 2012
    Publication date: July 24, 2014
    Applicant: Merck Patent GmbH
    Inventors: Amir Hossain Parham, Arne Buesing, Christof Pflumm, Teresa Mujica-Fernaud, Philipp Stoessel, Thomas Elberle, Frank Voges
  • Publication number: 20140197378
    Abstract: This invention relates to deuterated compounds that are useful in electroluminescent applications. It also relates to electronic devices in which the active layer includes such a deuterated compound.
    Type: Application
    Filed: January 14, 2013
    Publication date: July 17, 2014
    Applicant: E I DU PONT DE NEMOURS AND COMPANY
    Inventors: DANIEL DAVID LECLOUX, Hong Meng
  • Publication number: 20140194605
    Abstract: A SERS tag comprising a core comprising at least two aggregated particles of a SERS enhancing material wherein the contact point between the particles defines a crevice; and a reporter molecule having a length sufficiently short to fit into the crevice and a conjugated path length which is as large as possible, provided the overall reporter molecule length is maintained sufficiently short to fit into the crevice.
    Type: Application
    Filed: March 13, 2014
    Publication date: July 10, 2014
    Applicant: Cabot Security Materials, Inc.
    Inventors: Felicia Tam, Marcelo E. Piotti, Richard G. Freeman
  • Publication number: 20140179014
    Abstract: Nitric oxide probes including a compound represented by Formula, I, II, III, IV, V, VI or a combination thereof are provided. Methods of using these nitric oxide probes to detect nitric oxide are also provided.
    Type: Application
    Filed: December 20, 2013
    Publication date: June 26, 2014
    Inventors: Eric V. Anslyn, Youjun Yang, Michelle M. Adams
  • Publication number: 20140155490
    Abstract: The invention relates to protein binding interacting/binding compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions and methods for treating 5-HT2C disorders, including diseases and disorders mediated by GPCRs.
    Type: Application
    Filed: November 19, 2013
    Publication date: June 5, 2014
    Applicant: University of Florida Research Foundation, Inc.
    Inventor: Raymond G. Booth
  • Publication number: 20140138632
    Abstract: An amine-based compound and an organic light-emitting diode including the amine-based compound are provided. The amine-based compound may be used between a pair of electrodes of an organic light-emitting diode. For example, the amine-based compound may be used in an emission layer and/or between the emission layer and an anode (for example, in a hole injection layer, a hole transport layer, a functional layer having a hole injection ability and a hole transport ability). Accordingly, an organic light-emitting diode including a first electrode, a second electrode facing the first electrode, and an organic layer that is interposed between the first electrode and the second electrode, and includes the amine-based compound is provided.
    Type: Application
    Filed: March 13, 2013
    Publication date: May 22, 2014
    Inventors: Young-Kook Kim, Seok-Hwan Hwang, Hye-Jin Jung, Jun-Ha Park, Eun-Young Lee, Jin-O Lim, Sang-Hyun Han, Eun-Jae Jeong, Soo-Yon Kim, Jong-Hyuk Lee
  • Patent number: 8722743
    Abstract: The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A?), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A?) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH2C(=0)NH2, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from a single bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, and —CH2CH2CH2CH2—; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy.
    Type: Grant
    Filed: April 19, 2011
    Date of Patent: May 13, 2014
    Assignee: Oryzon Genomics S.A.
    Inventors: Alberto Ortega Munoz, Julio Castro-Palomino Laria, Matthew Colin Thor Fyfe
  • Publication number: 20140058101
    Abstract: The invention is directed to a phosphine compound represented by general formula (1) wherein R? and R? independently are selected from alkyl, cycloalkyl and 2-furyl radicals, or R? and R? are joined together to form with the phosphorous atom a carbon-phosphorous monocycle comprising at least 3 carbon atoms or a carbon-phosphorous bicycle; the alkyl radicals, cycloalkyl radicals, and carbon-phosphorous monocycle being unsubstituted or substituted by at least one radical selected from the group of alkyl, cycloalkyl, aryl, alkoxy, and aryloxy radicals; Cps is a partially substituted or completely substituted cyclopentadien-1-yl group, including substitutions resulting in a fused ring system, and wherein a substitution at the 1-position of the cyclopentadien-1-yl group is mandatory when the cyclopentadien-1-yl group is not part of a fused ring system or is part of an indenyl group. Also claimed is the use of these phosphines as ligands in catalytic reactions and the preparation of these phosphines.
    Type: Application
    Filed: October 29, 2013
    Publication date: February 27, 2014
    Applicant: Evonik Degussa GmbH
    Inventors: Herbert Plenio, Christoph Fleckenstein, Renat Kadyrov, Juan Almena, Axel Monsees, Thomas Riermeier
  • Patent number: 8658700
    Abstract: Treatment of CNS disorders with (1R,4S)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine; and (1S,4R)-trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is disclosed. A process for preparing 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine is also disclosed. The process includes the preparation of all four isomers of N-[4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]formamide, which are also useful.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: February 25, 2014
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Thomas Jerussi, Qun Kevin Fang, Mark G. Currie
  • Publication number: 20140034913
    Abstract: A condensation compound is represented by Formula 1, 2, or 3 where R1 to R24 and A to F are further defined in the detailed description.
    Type: Application
    Filed: January 8, 2013
    Publication date: February 6, 2014
    Inventors: So-Yeon KIM, Yoon-Hyun KWAK, Bum-Woo PARK, Jong-Won CHOI, Wha-II CHOI, Sun-Young LEE, Ji-Youn LEE, Jin-Young YUN
  • Patent number: 8614252
    Abstract: The subject invention provides crystalline R(+)-N-propargyl-1-aminoindan, pharmaceutical compositions and methods of manufacture thereof.
    Type: Grant
    Filed: January 8, 2010
    Date of Patent: December 24, 2013
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Anton Frenkel, Tamas Koltai
  • Patent number: 8597549
    Abstract: Disclosed are highly efficient multiphoton absorbing compounds and methods of their use. The compounds generally include a bridge of pi-conjugated bonds connecting electron donating groups or electron accepting groups. The bridge may be substituted with a variety of substituents as well. Solubility, lipophilicity, absorption maxima and other characteristics of the compounds may be tailored by changing the electron donating groups or electron accepting groups, the substituents attached to or the length of the pi-conjugated bridge. Numerous photophysical and photochemical methods are enabled by converting these compounds to electronically excited states upon simultaneous absorption of at least two photons of radiation. The compounds have large two-photon or higher-order absorptivities such that upon absorption, one or more Lewis acidic species, Lewis basic species, radical species or ionic species are formed.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: December 3, 2013
    Assignee: The California Institute of Technology
    Inventors: Brian Cumpston, Matthew Lipson, Seth R. Marder, Joseph W. Perry
  • Publication number: 20130302903
    Abstract: Nitric oxide probes comprising a compound represented by Formula, I, II, III, IV, V, VI or a combination thereof are provided. Methods of using these nitric oxide probes to detect nitric oxide are also provided.
    Type: Application
    Filed: October 4, 2012
    Publication date: November 14, 2013
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Eric V. Anslyn, Youjun Yang, Michelle M. Adams
  • Publication number: 20130299806
    Abstract: To provide an organic EL element material that is capable of enhancing the light emission efficiency and the lifetime of the element as compared to an ordinary organic EL element material, and an organic EL element using the same. Specifically, to provide an aromatic amine derivative represented by Ar1Ar2Ar3N, and an organic EL element using the same. Representative compounds include the following.
    Type: Application
    Filed: January 13, 2012
    Publication date: November 14, 2013
    Applicants: MITSUI CHEMICALS, INC, IDEMITSU KOSAN CO., LTD.
    Inventors: Tomoki Kato, Nobuhiro Yabunouchi, Takahiro Fujiyama
  • Patent number: 8563617
    Abstract: The present invention relates to aminotetraline derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminotetraline derivatives, and the use of such aminotetraline derivatives for therapeutic purposes. The aminotetraline derivatives are GlyT1 inhibitors.
    Type: Grant
    Filed: February 16, 2010
    Date of Patent: October 22, 2013
    Assignees: AbbVie Deutschland GmbH & Co. KG, Abbott Laboratories
    Inventors: Wilhelm Amberg, Michael Ochse, Udo Lange, Andreas Kling, Berthold Behl, Wilfried Homberger, Mario Mezler, Charles W. Hutchins
  • Patent number: 8546376
    Abstract: The invention relates to a series of compounds with particular activity as inhibitors of the serine-threonine kinase AKT. Also provided are pharmaceutical compositions comprising same as well as methods for treating cancer.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: October 1, 2013
    Assignee: Almac Discovery Limited
    Inventors: Mark Peter Bell, Timothy Harrison, Sumita Bhattacharyya, James Samuel Shane Rountree, Frank Burkamp, Stephen Price, Calum MacLeod, Richard Leonard Elliott, Phillip Smith, Toby Jonathan Blench, Colin Roderick O'Dowd, Lixin Zhang, Graham Peter Trevitt, Hazel Joan Dyke
  • Publication number: 20130234118
    Abstract: Embodiments of the present invention include an amine-based compound represented by Formula 1, an organic light-emitting diode including the amine-based compound, and an organic light-emitting apparatus including the amine-based compound.
    Type: Application
    Filed: December 5, 2012
    Publication date: September 12, 2013
    Applicant: SAMSUNG DISPLAY CO. LTD.
    Inventors: O-Hyun Kwon, Dong-Woo Shin, Kyul Han, Seul-Ong Kim, Byoung-Ki Choi
  • Publication number: 20130207046
    Abstract: The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
    Type: Application
    Filed: August 16, 2011
    Publication date: August 15, 2013
    Applicant: Merck Patent GmbH
    Inventors: Christof Pflumm, Amir Hossain Parham, Constanze Brocke, Elvira Montenegro, Frank Voges, Holger Heil, Arne Buesing
  • Patent number: 8497398
    Abstract: Several aromatic hydrocarbons di-substituted with a polyamine are described according to formulas selected from compounds 4, 7, 10, 15 and pharmaceutically acceptable salts thereof. The novel dimeric polyamines of the present invention demonstrate enhanced penetration into cells having an upregulated polyamine transport system, such as various types of cancer cells. The disclosed aromatic polyamine dimers provide highly efficient drugs for targeting cancer cells with active polyamine transporters.
    Type: Grant
    Filed: May 1, 2008
    Date of Patent: July 30, 2013
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Otto Phanstiel, IV, Navneet Kaur
  • Publication number: 20130187140
    Abstract: There is provided an electroluminescent composition. The composition includes a material having Formula I In Formula I: R1 is the same or different at each occurrence and is selected from D, alkyl, alkoxy, silyl, and siloxane, or adjacent R1 groups may be joined together to form a 5- or 6-membered aliphatic ring; Ar1 and Ar2 are the same or different and are aryl groups; a is an integer from 0 to 6; b is an integer from 0 to 2; and c is an integer from 0 to 3.
    Type: Application
    Filed: March 8, 2013
    Publication date: July 25, 2013
    Applicant: E I DU PONT DE NEMOURS AND COMPANY
    Inventor: E I DU PONT DE NEMOURS AND COMPANY
  • Publication number: 20130190407
    Abstract: The present invention relates to the different roles inorganic ion receptors have in cellular and body processes. The present invention features: (1) molecules which can modulate one or more inorganic ion receptor activities, preferably the molecule can mimic or block an effect of an extracellular ion on a cell having an inorganic ion receptor, more preferably the extracellular ion is Ca2+ and the effect is on a cell having a calcium receptor; (2) inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (3) nucleic acids encoding inorganic ion receptor proteins and fragments thereof, preferably calcium receptor proteins and fragments thereof; (4) antibodies and fragments thereof, targeted to inorganic ion receptor proteins, preferably calcium receptor protein; and (5) uses of such molecules, proteins, nucleic acids and antibodies.
    Type: Application
    Filed: December 28, 2012
    Publication date: July 25, 2013
    Applicant: NPS Pharmaceuticals, Inc.
    Inventor: NPS Pharmaceuticals, Inc.
  • Publication number: 20130181202
    Abstract: There is provided a compound represented by a specific formula, which has an absorption maximum at 400 nm or more and less than 720 nm in a UV-visible absorption spectrum, wherein a molar extinction coefficient is 10,000 mol?1·l·cm?1 or more at the absorption maximum wavelength, and a difference between a melting point and a deposition temperature (a melting point?a deposition temperature) is 31° C. or more.
    Type: Application
    Filed: March 7, 2013
    Publication date: July 18, 2013
    Applicant: FUJIFILM CORPORATION
    Inventor: FUJIFILM CORPORATION
  • Patent number: 8475804
    Abstract: The invention features compositions, methods, and kits useful for the treatment of filovirus-mediated diseases, e.g., hemorrhagic fever caused by Ebola virus, in an animal.
    Type: Grant
    Filed: February 22, 2010
    Date of Patent: July 2, 2013
    Assignees: U.S. Army Medical Research and Material Command, Zalicus, Inc.
    Inventors: Lisa M. Johansen, Joseph Lehár, Benjamin G. Hoffstrom, Gene G. Olinger, Andrea R. Stossel
  • Patent number: 8445541
    Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: May 21, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Matthew W. Davis
  • Patent number: 8440722
    Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., verapamil, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: May 14, 2013
    Assignee: Takeda Pharamceuticals U.S.A., Inc.
    Inventor: Matthew W. Davis
  • Patent number: 8440721
    Abstract: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of colchicine together with second active agents are also provided.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: May 14, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventor: Matthew W. Davis
  • Publication number: 20130116332
    Abstract: Provided herein are pharmaceutical compositions comprising transnorsertraline, salts and polymorphic forms of transnorsertraline, methods of making the compositions, and methods for their use for the treatment of CNS diseases, including depression.
    Type: Application
    Filed: December 3, 2010
    Publication date: May 9, 2013
    Inventors: Sharon M. Laughlin, Michael J. Sizensky, Surendra P. Singh, Harold Scott Wilkinson, Cai Gu Huang, Phillip James Bonasia, Susan S. D'souza
  • Publication number: 20130090386
    Abstract: The present invention relates to a compound of Formula 1, wherein: (A) is heteroaryl or aryl; each (A?), if present, is independently chosen from aryl, arylalkoxy, arylalkyl, heterocyclyl, aryloxy, halo, alkoxy, haloalkyl, cycloalkyl, haloalkoxy, and cyano, wherein each (A?) is substituted with 0, 1, 2, or 3 substituents independently chosen from halo, haloalkyl, haloalkoxy, aryl, arylalkoxy, alkyl, alkoxy, amido, —CH2C(=0)NH2, heteroaryl, cyano, sulfonyl, and sulfinyl; X is 0, 1, 2, or 3; (B) is a cyclopropyl ring, wherein (A) and (Z) are covalently bonded to different carbon atoms of (B); (Z) is —NH—; (L) is chosen from a single bond, —CH2—, —CH2CH2—, —CH2CH2CH2—, and —CH2CH2CH2CH2—; and (D) is an aliphatic carbocyclic group or benzocycloalkyl, wherein said aliphatic carbocyclic group or said benzocycloalkyl has 0, 1, 2, or 3 substituents independently chosen from —NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)(C1-C6 alkyl), alkyl, halo, amido, cyano, alkoxy, haloalkyl, and haloalkoxy.
    Type: Application
    Filed: April 19, 2011
    Publication date: April 11, 2013
    Inventors: Alberto Ortega Munoz, Juio Castro-Palomino Laria, Matthew Colin Thor Fyfe
  • Patent number: 8415396
    Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
    Type: Grant
    Filed: April 20, 2012
    Date of Patent: April 9, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Matthew W. Davis, Hengsheng Feng
  • Patent number: 8415395
    Abstract: Stable ultrapure colchicine compositions comprising ultrapure colchicine and a pharmaceutically acceptable excipient are described. The compositions can be tablets. Methods for preparing such compositions and methods of use are also disclosed. Methods of treating gout flares with colchicine compositions are also disclosed.
    Type: Grant
    Filed: April 19, 2012
    Date of Patent: April 9, 2013
    Assignee: Takeda Pharmaceuticals U.S.A., Inc.
    Inventors: Matthew W. Davis, Hengsheng Feng